← All trials
NCT07099014
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2025
- Primary completion
- Oct 13, 2028
- Completion date
- Apr 13, 2029
- First posted
- Aug 1, 2025
- Last posted
- Aug 1, 2025
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Assistance Publique - Hôpitaux de ParisLead sponsor
- Assistance Publique - Hôpitaux de ParisOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.